Regencell FY26 H1 net loss widens 187% to $5.3 million

• Regencell Bioscience posted a net loss of US$ 5.32 million for the six months ended Dec. 31, 2025, widening 187% from a year earlier; loss per share widened to US$ 1.08 cents from US$ 0.37 cents.
• Operating loss widened to US$ 5.34 million as total operating expenses climbed 170% to US$ 5.34 million, driven by general and administrative costs more than tripling to US$ 4.92 million.
• Other income fell to US$ 22,475 from US$ 124,222, while total assets dropped to US$ 3.01 million as of Dec. 31, 2025 from US$ 5.76 million as of June 30, 2025.
• Cash held steady at about US$ 2.4 million, while total liabilities rose to US$ 1.79 million from US$ 895,308.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regencell Bioscience Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-053892), on May 08, 2026, and is solely responsible for the information contained therein.